Gene Therapy for Transfusion-Dependent β-Thalassemia: Results and Remaining Challenges
Inherited anemia requiring transfusions and iron overload management
A review reports that two autologous gene therapies for transfusion-dependent β-thalassemia (TDT) achieved high rates of transfusion independence in clinical trials, while conditioning toxicity, long-term safety, and access remain concerns. Published in Therapeutic Advances in Rare Disease, the paper summarizes clinical-trial and real-world evidence.
β-thalassemia is an inherited hemoglobin disorder characterized by ineffective red-cell production and chronic anemia. Severe cases require regular transfusions for life. Variants in the β-globin gene (HBB) reduce β-globin production, disrupting its balance with α-globin and impairing red-cell production.
Standard TDT care consists of regular red-cell transfusions and iron chelation therapy. Transfusions relieve anemia and suppress ineffective red-cell production, but repeated transfusions cause iron to accumulate in the body. Iron chelation removes accumulated iron and is used to reduce organ damage from iron overload.
Transfusion independence with two autologous gene therapies
Two autologous gene therapies have been approved in the United States. Both genetically modify a patient’s own hematopoietic stem and progenitor cells outside the body and then reinfuse them. Betibeglogene autotemcel (beti-cel) adds a functional β-globin gene. Exagamglogene autotemcel (exa-cel) uses CRISPR-Cas9 gene editing to alter an erythroid-specific regulatory region of BCL11A, reactivating fetal hemoglobin production.
According to the review, in the HGB-207 trial of beti-cel, 20 of 22 evaluable patients (91%) achieved transfusion independence. In this trial, transfusion independence was defined as maintaining a weighted average hemoglobin concentration of at least 9 g/dL for a minimum of 12 months without additional transfusions, beginning 60 days after the last transfusion. In HGB-212, which included more severe genotypes, 16 of 18 patients (89%) achieved and maintained transfusion independence; median follow-up was about 48 months.
The exa-cel CLIMB THAL-111 trial enrolled 52 patients aged 12–35 years. Of the 35 evaluable patients, 32 (91%) achieved transfusion independence. Median follow-up was 20.4 months. These results come from separate trials, and no head-to-head trial has compared the two therapies, so the figures cannot establish which is superior.
Conditioning toxicity and access remain challenges
Challenges remain despite these results. Gene therapy requires busulfan-based myeloablative conditioning to make space in the bone marrow for the modified cells to engraft, and this can cause short- and long-term toxicity. The risk of permanent impairment of fertility is also a consideration in counseling. Centralized manufacturing and high treatment costs may limit access.
Transfusion independence does not mean that every aspect of the disease has resolved. In some patients, markers of ineffective red-cell production did not normalize completely, and existing iron overload still requires separate management. Further follow-up is needed to establish long-term safety and durability of benefit. The paper also has the limitation of being a review rather than a formal systematic review.
Key evidence is available in the full review.
Beta-thalassemia is an inherited blood disorder characterized by chronic anemia, ineffective erythropoiesis, and in its most severe form, lifelong transfusion dependence. The standard of care for transfusion-dependent thalassemia (TDT) is regular red blood cell transfusions to relieve anemia and suppress ineffective erythropoiesis, and iron chelation therapy to mitigate morbidity and mortality related to iron overload. Allogeneic hematopoietic stem cell transplantation is a curative option but is only available to patients with an appropriate donor and carries risks of graft-versus-host disease and other transplant-related morbidity. In recent years, the therapeutic landscape for TDT has changed dramatically with the approval of two autologous gene therapies in the United States: betibeglogene autotemcel (beti-cel) and exagamglogene autotemcel (exa-cel). Clinical trials for both gene therapies have demonstrated high rates of sustained transfusion independence for both pediatric and adult age groups. However, despite these advances, challenges remain. Gene therapy requires myeloablative busulfan-based conditioning chemotherapy, which carries the risk of short- and long-term toxicities. Furthermore, centralized manufacturing and high treatment costs are likely to limit access to gene therapy. In this review, we discuss the available clinical trial and real-world data for beti-cel and exa-cel, and describe how gene therapy fits into the current treatment landscape, introducing areas of ongoing investigation to improve access to transformative therapy for TDT. Update on beta-thalassemia treatments: Focus on Gene therapy. Beta-thalassemia is caused by mutations in the beta-globin gene that lead to decreased hemoglobin levels (anemia). People with transfusion-dependent beta-thalassemia (TDT) require lifelong blood transfusions to treat their anemia and related complications. Because chronic blood transfusion therapy causes iron buildup in the body, patients also must receive long-term iron chelation therapy.
For patients with transfusion-dependent β-thalassemia who lack a suitable donor, autologous gene therapy offers the possibility of no longer needing regular transfusions. Treatment discussions should consider transfusion independence rates alongside the toxicity of busulfan conditioning, fertility preservation, a manufacturing and treatment timeline spanning several months, cost, and access to treatment centers. Management of existing iron overload and long-term follow-up may continue after transfusions stop. This review gathers evidence to inform treatment choices, but it does not establish which therapy is more suitable for a particular patient or whether its effects will last for life.